Skip to content

CHPA adds two new board and Executive Committee Members, names 2025 chair-elect

Greg Bradley will assume the two-year appointment as Board Chair in March 2025, when current CHPA Board Chair, Lisa Paley, president of Haleon’s North America Region, concludes her term.

Table of Contents

 

PHILADELPHIA – The Consumer Healthcare Products Association (CHPA) today announced the election of two new board members following its November Board of Directors meeting in Philadelphia. The Association also announced the appointment of current CHPA board member, Greg Bradley, CEO of Foundation Consumer Healthcare, as chair-elect of the CHPA board of directors. Bradley will assume the two-year appointment as Board Chair in March 2025, when current CHPA Board Chair, Lisa Paley, president of Haleon’s North America Region, concludes her term.

Newly elected board members at this meeting include:

·         Jim Lepis, senior director of Marketing, Hisamitsu America, Inc., Hisamitsu Pharmaceutical Co., Inc., and

·         Neil Lister, chief commercial officer CSCI & Senior Vice President, Perrigo.

 Additionally, Lister and current board member John Ferris Jr., executive vice president, Global Consumer, Bausch + Lomb, were elected to CHPA’s Executive Committee.

“Lisa and I are delighted to welcome Jim and Neil to the CHPA Board of Directors, and John and Neil to the Executive Committee,” said CHPA President & CEO Scott Melville. “CHPA is fortunate to have exceptional business leaders volunteer their time to direct the association’s priorities and oversee its governance. We are also extremely pleased at the appointment of Greg Bradley as chair-elect of CHPA’s Board. Greg’s decades of experience in consumer healthcare, with both large multinational companies, and now as the leader of Foundation Consumer Healthcare – a successful over-the-counter consumer healthcare company – will tremendously benefit CHPA as we navigate an increasingly complex and diverse self-care marketplace.”

View the full CHPA Board of Directors.

Comments

Latest